Chugai Pharma Taiwan Ltd.
↗Taipei, Taiwan
Chugai Pharma Taiwan Ltd. (CPT) is the wholly-owned Taiwan subsidiary of Chugai Pharmaceutical Co., Ltd. (Japan), which is a member of the global Roche Group. Established in 1988, the company serves as a strategic hub for the clinical development, regulatory submission, and commercialization of innovative biologics and specialty medicines in the Taiwan market. CPT is specifically focused on addressing unmet medical needs through Chugai's proprietary antibody engineering technologies.
The company maintains a strong presence in high-specialty therapeutic areas including oncology, hematology, immunology, and rare diseases. It operates as a fully integrated pharmaceutical entity in Taiwan, managing everything from early-phase clinical development to National Health Insurance (NHI) price negotiations and marketing. CPT is recognized for its commitment to ESG and talent development, frequently winning industry awards for its corporate social responsibility initiatives.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Biotechnology and Specialty Therapeutics
SIZE & FINANCIALS
Employees:51-200
Revenue:$50M-$100M (estimated for Taiwan entity)
Founded:1988
Ownership:subsidiary
Status:operating
FUNDING
Investors:Chugai Pharmaceutical Co., Ltd., Roche (Majority stakeholder of parent)
STOCK
Exchange:TYO
Ticker:4519
Market Cap:$74.4B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial (PiaSky launched May 2025)
Modalities:mAb, Bispecific antibody, Recycling Antibody, Small molecule
Active Trials:15
Trial Phases:Phase 1: 2 | Phase 2: 5 | Phase 3: 8
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Chugai Pharmaceutical Co., Ltd.
Acquired By:Chugai Pharmaceutical Co., Ltd. (Parent), Roche Group (Majority Owner) (2002-10-01)
Key Partnerships:Roche (Strategic alliance for global development), Eli Lilly (Out-licensing of orforglipron), Verastem Oncology (Out-licensing of avutometinib)
COMPETITION
Position:Leader
Competitors:Amgen Taiwan, AstraZeneca Taiwan, Takeda Taiwan, Jazz Pharmaceuticals, Alexion (AstraZeneca Rare Disease)
LEADERSHIP
Key Executives:
Yuji Habara - President and General Manager
Susan Chou - HR Director
Kiyoshi Yamanoue - Associate Corporate Planning Director
Board Members:Yuji Habara
LINKS
Website:chugai.com.tw
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Chugai Pharma Taiwan Ltd.. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.